| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UGT1A1 |
| Uniprot No | P22309 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-490aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHAGKILLIPVDGSHWLSMLGAIQQLQQ RGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFEN DSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDP FLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSD HMTFLQRVKNMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSAS VWLFRSDFVKDYPRPIMPNMVFVGGINCLHQNPLSQEFEAYINASGEHGI VVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILV KWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAK RMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPV EPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLD |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UGT1A1重组蛋白的3篇代表性文献的简要信息：
1. **文献名称**：*Expression and characterization of recombinant human UDP-glucuronosyltransferase 1A1 (UGT1A1) in baculovirus-infected insect cells*
**作者**：Ritter JK, Chen F, Sheen YY
**摘要**：该研究利用杆状病毒-昆虫细胞系统成功表达了人源UGT1A1重组蛋白，并对其酶动力学特性进行了分析，证实其在胆红素和药物底物(如依托泊苷)的葡萄糖醛酸化反应中具有活性。
2. **文献名称**：*Functional characterization of UGT1A1 variants involved in Gilbert’s syndrome using recombinant proteins*
**作者**：Guillemette C, Lévesque É, Harvey M
**摘要**：通过构建UGT1A1常见基因多态性(如*UGT1A1*28)的重组蛋白，分析了启动子区TA重复序列对酶表达水平和活性的影响，揭示了其与Gilbert综合征的关联机制。
3. **文献名称**：*Optimization of recombinant UGT1A1 production in Escherichia coli for studies on drug metabolism*
**作者**：Mano Y, Usui T, Kamimura H
**摘要**：研究优化了在大肠杆菌中表达UGT1A1重组蛋白的条件，通过融合标签纯化获得高活性蛋白，并验证其在体外药物代谢研究(如伊立替康代谢物SN-38的葡萄糖醛酸化)中的应用潜力。
这些文献涵盖了UGT1A1重组蛋白的表达系统开发、基因多态性功能研究及药物代谢应用等方向。
**Background of UGT1A1 Recombinant Protein**
UGT1A1 (UDP-glucuronosyltransferase 1A1) is a critical enzyme in phase II drug metabolism, responsible for conjugating hydrophobic substrates—such as bilirubin, hormones, and xenobiotics—with glucuronic acid to enhance their water solubility and facilitate excretion. This enzyme belongs to the UGT superfamily, which plays a central role in detoxification and metabolic homeostasis. UGT1A1 is predominantly expressed in the liver and intestines, where it ensures the clearance of endogenous toxins (e.g., unconjugated bilirubin) and metabolizes therapeutic drugs, including irinotecan, acetaminophen, and HIV protease inhibitors.
Genetic polymorphisms in the *UGT1A1* gene, notably the *UGT1A1*28 variant, are linked to reduced enzyme activity, leading to conditions like Gilbert’s syndrome and severe hyperbilirubinemia (Crigler-Najjar syndrome). These variations also influence drug efficacy and toxicity, underscoring the need for UGT1A1-related pharmacogenetic studies.
Recombinant UGT1A1 protein is produced via heterologous expression systems (e.g., *E. coli*, insect, or mammalian cells) to study its enzymatic properties, substrate specificity, and interactions with inhibitors/inducers. This engineered protein retains catalytic activity, enabling in vitro analyses of glucuronidation kinetics and metabolic profiling without requiring human tissue samples. Applications span drug development (predicting metabolism/toxicity), personalized medicine (dose optimization based on genetic variants), and disease modeling (e.g., hyperbilirubinemia mechanisms).
Despite its utility, challenges persist in replicating native post-translational modifications and enzyme stability in vitro. Advances in expression systems and structural biology continue to refine recombinant UGT1A1’s functionality, supporting its role as a vital tool in pharmacology and toxicology research.
×
